Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center

Ruxolitinib in PV: The RESPONSE Trial

August 4th 2021

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.

The JAK2 Pathway in Polycythemia Vera

August 4th 2021

A specialist in hematologic malignancies provides an overview of the JAK2 pathway as it relates to myeloproliferative neoplasms such as polycythemia vera.

PV Treatment Options and Dosing

July 28th 2021

Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.

Risk Stratification and Treatment Considerations in PV

July 28th 2021

A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.

Myeloproliferative Neoplasms: Diagnosing Polycythemia Vera

July 28th 2021

An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Advances in the Management of MPNs

July 7th 2020

Essential Thrombocythemia: Treatment Optimization

July 7th 2020

Classifying Patients With Essential Thrombocythemia

July 7th 2020

Primary Myelofibrosis: Trials of Interest

July 7th 2020

JAK2 Inhibitor Selection for Primary Myelofibrosis

July 7th 2020

Fedratinib for Primary Myelofibrosis

July 7th 2020

Ruxolitinib and Surgical Interventions

July 7th 2020

Ruxolitinib for Primary Myelofibrosis

July 7th 2020